Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
British Journal of Cancer|December 17, 2019
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanomaAvinash Gupta, Christopher Towers, Frances Willenbrock, et al.
Plos One|September 15, 2016
Targeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for DiagnosisPamela J Kaisaki, Anthony Cutts, Niko Popitsch, et al.
Plos Medicine|February 15, 2017
Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health ServiceAngela Hamblin, Sarah Wordsworth, Jilles M Fermont, et al.
Cytometry. Part B, Clinical Cytometry|June 15, 2019
A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-10<sup>6</sup> and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 PatientsPrashant R Tembhare, Papagudi G Subramanian Pg, Sitaram Ghogale, et al.
European Journal of Cancer (Oxford, England : 1990)|November 8, 2022
Tumour infiltrating B cells discriminate checkpoint blockade-induced responsesSara Valpione, Luca G Campana, John Weightman, et al.
Cancer|October 18, 2018
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancerToby A Eyre, Graham P Collins, Avinash Gupta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2012
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumorsSuzanne Leijen, Mark R Middleton, Patricia Tresca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic MelanomaMark R Middleton, Cheryl McAlpine, Victoria K Woodcock, et al.
Nature Communications|May 21, 2026
Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trialRebecca J Lee, Dominic G Rothwell, Nigel Smith, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2023
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAF<sup>V600</sup> mutant advanced melanoma (INTERIM)Alimu Dayimu, Avinash Gupta, Rubeta N Matin, et al.
Pageof 6